Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MT1988 · 1 trial · 1 indication
Data will be analysed using descriptive statistics across four dose levels and versus placebo.
| Arm | Type | Description |
|---|---|---|
| MT1988 Dose 1 | EXPERIMENTAL | MT1988 Dose Level 1 (oral, twice daily) |
| MT1988 Dose 2 | EXPERIMENTAL | MT1988 Dose Level 2 (oral, twice daily) |
| MT1988 Dose 3 | EXPERIMENTAL | MT1988 Dose Level 3 (oral, twice daily) |
| MT1988 Dose 4 | EXPERIMENTAL | MT1988 Dose Level 4 (oral, twice daily) |
| Placebo | PLACEBO_COMPARATOR | Placebo (oral, twice daily) |
| Name | Type | Description |
|---|---|---|
| MT1988 | DRUG | Active Drug |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: * healthy volunteers * providing informed consent * for females of child-bearing potential with fertile male partner - willing to comply with contraception requirements Exclusion Criteria: * no current or past condition which may compromise the study objectives or participant ...
MT1988 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and pharmacokinetics. The drug is not approved for any medical condition and remains in early-stage clinical testing.
The molecular target of MT1988 has not been disclosed. As a small molecule in Phase 1 development, its mechanism of action is not publicly specified. The available clinical data focuses on safety and pharmacokinetic parameters in healthy volunteers rather than target engagement.
MT1988 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker YCBD. The company is conducting clinical research on this investigational small molecule, with the drug currently in Phase 1 development.
MT1988 is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 42 healthy volunteers in the United Kingdom. The study was randomized, double-blind, and placebo-controlled, evaluating the safety and pharmacokinetics of multiple doses of MT1988.
MT1988 has one completed clinical trial, identified as NCT06728176, titled 'Safety and PK of Multiple Doses of MT1988.' This Phase 1 study enrolled 42 healthy volunteers aged 18 years and older in the United Kingdom. The trial was randomized, double-blind, and placebo-controlled.
MT1988 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy volunteers was designed to assess safety and pharmacokinetics, but the drug has not received regulatory approval for any use.